Page 13 - Genomic Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Joel Dudley opens AAPS biotechnology conference with talk examining current economic environment for biotechnology firm

The National Institute for Clinical Excellence (NICE) has published new guidelines for the best surgery for some women who have advanced ovarian cancer. Maximal cytoreductive surgery is a major operation that aims to remove all visible disease when t

The combination of olaparib and the investigational ATR inhibitor ceralasertib induced antitumor responses in children and adolescents with DNA repair-deficient tumors, according to phase 1 results of the AcSé-ESMART trial.The data, presented at American Association for Cancer Research Annual Meeting, also showed ceralasertib (AZD6738, AstraZeneca) plus olaparib (Lynparza, AstraZeneca) — a

The combination of PARP and ATR inhibition with olaparib and ceralasertib was tolerable but showed limited efficacy in pediatric patients with advanced malignancies harboring DNA replication stress and DNA repair deficiencies, according to findings from arm N of the phase 1/2 AcSé-ESMART trial.

Washington, DC (PRWEB) April 10, 2023 -- The Society for RNA Therapeutics is pleased to announce the members of its charter board of directors. The mission of